Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North central cancer treatment group results

Evanthia Galanis, Jan Craig Buckner, Patrick A. Burch, Paul L. Schaefer, Robert P. Dinapoli, Paul J. Novotny, B. W. Scheithauer, Kendrith M. Rowland, Allen M. Vukov, James A. Mailliard, Roscoe F. Morton

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/μL in 23% and platelet nadirs less than 25,000/μL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.

Original languageEnglish (US)
Pages (from-to)2953-2958
Number of pages6
JournalJournal of Clinical Oncology
Volume16
Issue number9
StatePublished - Sep 1998

Fingerprint

Procarbazine
Mechlorethamine
Vincristine
Glioma
Neoplasms
Oligodendroglioma
Therapeutics
Multivariate Analysis
Drug Therapy
Survival
Astrocytoma
Glioblastoma
Neutropenia
Leukocytes
Blood Platelets
Research Personnel
Prospective Studies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma : North central cancer treatment group results. / Galanis, Evanthia; Buckner, Jan Craig; Burch, Patrick A.; Schaefer, Paul L.; Dinapoli, Robert P.; Novotny, Paul J.; Scheithauer, B. W.; Rowland, Kendrith M.; Vukov, Allen M.; Mailliard, James A.; Morton, Roscoe F.

In: Journal of Clinical Oncology, Vol. 16, No. 9, 09.1998, p. 2953-2958.

Research output: Contribution to journalArticle

Galanis, E, Buckner, JC, Burch, PA, Schaefer, PL, Dinapoli, RP, Novotny, PJ, Scheithauer, BW, Rowland, KM, Vukov, AM, Mailliard, JA & Morton, RF 1998, 'Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North central cancer treatment group results', Journal of Clinical Oncology, vol. 16, no. 9, pp. 2953-2958.
Galanis, Evanthia ; Buckner, Jan Craig ; Burch, Patrick A. ; Schaefer, Paul L. ; Dinapoli, Robert P. ; Novotny, Paul J. ; Scheithauer, B. W. ; Rowland, Kendrith M. ; Vukov, Allen M. ; Mailliard, James A. ; Morton, Roscoe F. / Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma : North central cancer treatment group results. In: Journal of Clinical Oncology. 1998 ; Vol. 16, No. 9. pp. 2953-2958.
@article{3651d295d45549b2b74cedc6a11b6006,
title = "Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North central cancer treatment group results",
abstract = "Purpose: Previous investigators have reported responses in 52{\%} of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. Results: Of 61 patients assessable for response, eight responded (13{\%}), with one complete response (CR). Responses were as follows: low-grade gliomas, 19{\%}; anaplastic astrocytomas, 11{\%}; anaplastic oligodendrogliomas or oligoastrocytomas, 25{\%}; and glioblastomas, 4.3{\%}. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/μL in 23{\%} and platelet nadirs less than 25,000/μL in 13{\%} of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21{\%} of patients (severe in 3{\%}) and severe dermatologic reactions in 8{\%}. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25{\%} and 19{\%}, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.",
author = "Evanthia Galanis and Buckner, {Jan Craig} and Burch, {Patrick A.} and Schaefer, {Paul L.} and Dinapoli, {Robert P.} and Novotny, {Paul J.} and Scheithauer, {B. W.} and Rowland, {Kendrith M.} and Vukov, {Allen M.} and Mailliard, {James A.} and Morton, {Roscoe F.}",
year = "1998",
month = "9",
language = "English (US)",
volume = "16",
pages = "2953--2958",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "9",

}

TY - JOUR

T1 - Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma

T2 - North central cancer treatment group results

AU - Galanis, Evanthia

AU - Buckner, Jan Craig

AU - Burch, Patrick A.

AU - Schaefer, Paul L.

AU - Dinapoli, Robert P.

AU - Novotny, Paul J.

AU - Scheithauer, B. W.

AU - Rowland, Kendrith M.

AU - Vukov, Allen M.

AU - Mailliard, James A.

AU - Morton, Roscoe F.

PY - 1998/9

Y1 - 1998/9

N2 - Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/μL in 23% and platelet nadirs less than 25,000/μL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.

AB - Purpose: Previous investigators have reported responses in 52% of patients treated with mechlorethamine (nitrogen mustard), vincristine, and procarbazine (MOP) for recurrent glioma. To confirm these promising results, we conducted a phase II prospective study. Patients and Methods: Sixty-three patients with histologic confirmation of recurrent glioma were treated with the MOP regimen. Patients with or without prior chemotherapy received nitrogen mustard 3 mg/m2 or 6 mg/m2, respectively, intravenously on days 1 and 8 plus vincristine 2 mg/m2 intravenously on days 1 and 8, and procarbazine 100 mg/m2 orally on days 1 to 14. Cycles were repeated every 28 days. Results: Of 61 patients assessable for response, eight responded (13%), with one complete response (CR). Responses were as follows: low-grade gliomas, 19%; anaplastic astrocytomas, 11%; anaplastic oligodendrogliomas or oligoastrocytomas, 25%; and glioblastomas, 4.3%. The most common toxicity was myelosuppression with leukocyte nadirs less than 1,000/μL in 23% and platelet nadirs less than 25,000/μL in 13% of patients. Two patients died of infection in the setting of neutropenia. Nonhematologic toxicity included neurosensory changes in 21% of patients (severe in 3%) and severe dermatologic reactions in 8%. In multivariate analysis, Eastern Cooperative Oncology group (ECOG) performance status (PS) was the best predictor for response to chemotherapy (P = .01) and time to progression (P = .008), while PS and grade were the most important predictors of survival (P = .002 and .05, respectively). Conclusion: This study did not confirm the high response rate previously reported in recurrent gliomas. Patients with recurrent anaplastic oligodendrogliomas or oligoastrocytomas and recurrent low-grade gliomas had the highest response rates (25% and 19%, respectively). In multivariate analysis, ECOG PS was the best predictor of response, while PS and tumor grade were the most important predictors of survival.

UR - http://www.scopus.com/inward/record.url?scp=0031692882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031692882&partnerID=8YFLogxK

M3 - Article

C2 - 9738563

AN - SCOPUS:0031692882

VL - 16

SP - 2953

EP - 2958

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 9

ER -